Jerome T. Mettetal

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Rethinking the role of synergy calculations in the next century of drug combination discovery.

Rethinking the role of synergy calculations in the next century of drug combination discovery.

Journal: Med (New York, N.Y.)

Published: October 22, 2025

Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.

Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.

Journal: Molecular cancer therapeutics

Published: August 22, 2025

Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.

Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.

Journal: Molecular cancer therapeutics

Published: July 30, 2025

Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.

Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.

Journal: NPJ systems biology and applications

Published: August 08, 2024

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.

Journal: Leukemia

Published: February 15, 2024

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 12, 2023

Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia.

Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia.

Journal: Blood cancer discovery

Published: May 08, 2023

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Journal: Cancer discovery

Published: April 04, 2023

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.

Journal: Communications biology

Published: January 27, 2023

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.

Journal: NPJ systems biology and applications

Published: August 22, 2022

Importance of Stability Analysis When Using Nonlinear Semimechanistic Models to Describe Drug-Induced Hematotoxicity.

Importance of Stability Analysis When Using Nonlinear Semimechanistic Models to Describe Drug-Induced Hematotoxicity.

Journal: CPT: pharmacometrics & systems pharmacology

Published: January 23, 2020

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.

Journal: Science translational medicine

Published: August 24, 2019

Showing 1-12 of 41

Last Updated: 09/26/2026